Pharmacy News

Bajaj Healthcare launches generic favipiravir tablets for Covid-19 treatment, Health News, ET HealthWorld

Representative image

New Delhi, May 4 : Drug firm Bajaj Healthcare on Tuesday announced the launch of its antiviral Favipiravir tablets under the brand name ‘Favijaj‘ used for the treatment of mild to moderate Covid-19 infections in the country. The company has received approval from India’s drug regulator DCGI to manufacture and market the tablets, Bajaj Healthcare said in a BSE filing.

“We hope the availability of an effective treatment such as Favijaj will considerably ease the pressure and offer patients much-needed and timely therapy options,” Bajaj Healthcare Joint MD Anil Jain said.

The company has successfully developed the active pharmaceutical ingredient (API) and the formulation for favipiravir through its own in-house R&D team, Bajaj Healthcare said.

Shares of Bajaj Healthcare closed at Rs 583.05 per scrip on BSE, up steep 10.85 percent from its previous close. AKT SHW SHW

Follow and connect with us on , Facebook, Linkedin

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Ad Block Detected

Welcome to Mediexpose, Please support our journalism by allowing ads. With support from readers like you, we can continue to deliver the best. You can support us free by simply allowing ads.